Shares of Viking Therapeutics plunged Tuesday after the company released midstage trial data on its obesity pill that disappointed investors. CNBC’s Angelica Peebles joins 'Money Movers' to discuss.
Breakdown
- Viking Therapeutics' shares dropped over 40% after new obesity drug trial data was released. 1s
- Trial participants lost about 12% of body weight at the highest dose over three months. 18s
- 28% of participants stopped taking the drug, with 20% discontinuing due to side effects, mainly nausea. 27s
- Analysts question the drug's competitiveness and Viking's potential as a major market player. 54s
- Uncertainty remains about the future demand for oral obesity drugs amid strong competition. 1m 49s